| Cellular and molecular determinants of cisplatin resistance RP Perez European Journal of Cancer 34 (10), 1535-1542, 1998 | 557 | 1998 |
| Malignancy‐related pericardial effusion. 127 cases from the roswell park cancer institute JD Wilkes, P Fidias, L Vaickus, RP Perez Cancer 76 (8), 1377-1387, 1995 | 212 | 1995 |
| Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2–negative metastatic breast cancer AF Schott, LJ Goldstein, M Cristofanilli, PA Ruffini, S McCanna, ... Clinical Cancer Research 23 (18), 5358-5365, 2017 | 196 | 2017 |
| Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines SW Johnson, RP Perez, AK Godwin, AT Yeung, LM Handel, RF Ozols, ... Biochemical pharmacology 47 (4), 689-697, 1994 | 188 | 1994 |
| Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha–targeting antibody–drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary … KN Moore, LP Martin, DM O’Malley, UA Matulonis, JA Konner, RP Perez, ... Journal of clinical oncology 35 (10), 1112-1118, 2017 | 172 | 2017 |
| Mechanisms and modulation of resistance to chemotherapy in ovarian cancer RP Perez, TC Hamilton, RF Ozols, RC Young Cancer 71 (S4), 1571-1580, 1993 | 159 | 1993 |
| Ovarian cancer biology RP Perez, AK Godwin, TC Hamilton, RF Ozols Seminars in oncology 18 (3), 186-204, 1991 | 148 | 1991 |
| Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule RJ Schilder, FP LaCreta, RP Perez, SW Johnson, JM Brennan, A Rogatko, ... Cancer research 54 (3), 709-717, 1994 | 139 | 1994 |
| A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines RP Perez, AK Godwin, LM Handel, TC Hamilton European Journal of Cancer 29 (3), 395-399, 1993 | 112 | 1993 |
| Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors KN Moore, H Borghaei, DM O'Malley, W Jeong, SM Seward, TM Bauer, ... Cancer 123 (16), 3080-3087, 2017 | 108 | 2017 |
| Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas JM Pipas, SE Mitchell, RJ Barth Jr, R Vera-Gimon, J Rathmann, LP Meyer, ... International Journal of Radiation Oncology* Biology* Physics 50 (5), 1317-1322, 2001 | 101 | 2001 |
| Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems RP Perez, TC Hamilton, RF Ozols Pharmacology & therapeutics 48 (1), 19-27, 1990 | 100 | 1990 |
| Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers L Pendyala, Y Kidani, R Perez, J Wilkes, RJ Bernacki, PJ Creaven Cancer letters 97 (2), 177-184, 1995 | 98 | 1995 |
| Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. NJ Meropol, M Porter, LE Blumenson, MJ Lindemann, RP Perez, ... Clinical cancer research: an official journal of the American Association …, 1996 | 96 | 1996 |
| Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of … LP Martin, JA Konner, KN Moore, SM Seward, UA Matulonis, RP Perez, ... Gynecologic oncology 147 (2), 402-407, 2017 | 95 | 2017 |
| Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204. RP Perez, MJ Riese, KD Lewis, MN Saleh, A Daud, J Berlin, JJ Lee, ... Journal of Clinical Oncology 35 (15_suppl), 3003-3003, 2017 | 90 | 2017 |
| Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850) RP Perez, LD Lewis, AP Beelen, AJ Olszanski, N Johnston, CH Rhodes, ... Clinical cancer research 12 (23), 7079-7085, 2006 | 90 | 2006 |
| A phase Ib/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma IM Ghobrial, CJ Liu, RA Redd, RP Perez, R Baz, O Zavidij, ... Clinical Cancer Research 26 (2), 344-353, 2020 | 85 | 2020 |
| Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma JM Pipas, RJ Barth, B Zaki, MJ Tsapakos, AA Suriawinata, MA Bettmann, ... Annals of surgical oncology 12, 995-1004, 2005 | 85 | 2005 |
| A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer LJ Goldstein, RP Perez, D Yardley, LK Han, JM Reuben, H Gao, ... Breast Cancer Research 22, 1-9, 2020 | 83 | 2020 |